



Structural abnormalities of the heart and vascular system in CKD & Dialysis

-
Thick but weak





Kerstin Amann
Nephropathology,
Dept. of Pathology, University of Erlangen-Nürnberg
Krankenhausstr. 8-10
91054 Erlangen, Germany

Cardiovascular pathology in CKD



LVH

atherosclerosis

calcification



microarteriopathy



arteriosclerosis

fibrosis


reduction in capillarisation

Cardiovascular pathology in CKD - crosstalk between kidney and cardiovascular system




- LVH
- cardiac fibrosis
- impaired angioadaptation with reduced ischemia tolerance
(role of VEGF and the sympathetic nervous system)
- accelerated arterio- and atherosclerosis
(calcification and inflammation)

Cardiovascular pathology in CKD - crosstalk between kidney and cardiovascular system




- **LVH: is very common and develops early on in CKD**
- cardiac fibrosis
- impaired angioadaptation with reduced ischemia tolerance
(role of VEGF and the sympathetic nervous system)
- accelerated arterio- and atherosclerosis
(calcification and (micro-) inflammation)

Prevalence of LV disorders in CKD





84% of patients starting dialysis already show LV alterations




time until development of end-stage heart failure

„Uremic cardiomyopathy“ / cardiomyopathy in advanced CKD




control




CKD


Relative heart weight and left ventricular weight



Morphology of the myocardium in experimental CKD



sham





SNX




- LVH already present after 3 weeks (20 - 60% increase in LV weight)
- LV contractility: - 40%
- prevented and reversed (!) by ACE-i and mTOR inhibition

LVH in SNX is accompanied by increased apoptosis and loss of cardiomyocytes

SNX




sham



Nakamura et al. 2010:
↑cyclin D2, ↑PCNA, ↓CDK-inhibitor p27 (as novel markers of LVH)



- myocyte loss (-25%) in CKD predisposes to cardiac failure !
- experimentally prevented by ACE-i and mTOR inhibition!

Cardiovascular pathology in CKD - crosstalk between kidney and cardiovascular system



- LVH
- cardiac fibrosis
- impaired angioadaptation with reduced ischemia tolerance
(role of VEGF and the sympathetic nervous system)
- accelerated arterio- and atherosclerosis
(calcification and (micro-) inflammation)


Increased volume density of the myocardial interstitial tissue in CKD



- early and specific activation of myocardial interstitial cells in CKD
- pathogenetic role of PTH, P, AngII and ET-1 (via TGF-β)

Functional consequences of cardiac fibrosis

- reduced LV compliance
- altered stress – strain relationship
- arrhythmia
 - interposition of fibrous tissue with high electrical resistance
 - local delay in spread of action potential
 - reentry type of arrhythmia



→ sudden cardiac death

Cardiovascular pathology in CKD - crosstalk between kidney and cardiovascular system



- LVH
 - FGF23, a new kid on the block ?
- cardiac fibrosis
- impaired angioadaptation with reduced ischemia tolerance
(role of VEGF and the sympathetic nervous system)
- accelerated arterio- and atherosclerosis
(calcification and inflammation)

Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney Disease

Orlando M. Gutiérrez, James L. Januzzi, Tamara Isakova, Karen Laliberte, Kelsey Smith, Gina Collerone, Ammar Sarwar, Udo Hoffmann, Erin Coglianese, Robert Christenson, Thomas J. Wang, Christopher deFilippi and Myles Wolf




Figure 1. Mean concentrations of log FGF-23 and phosphate according to level of kidney function. Bars represent SDs; shaded areas, normal ranges for each analyte.





Figure 2. Correlation between log FGF-23 and LVMI ($r=0.27$, $P<0.001$). □ Indicates non-CKD subjects; ■, subjects with CKD.

FGF23 induces left ventricular hypertrophy


Christian Faul,^{1,2} Ansel P. Amaral,^{1,2} Behzad Oskouei,³ Ming-Chang Hu,^{4,5,6} Alexis Sloan,^{1,2} Tamara Isakova,¹ Orlando M. Gutiérrez,⁷ Robier Aguilon-Prada,¹ Joy Lincoln,⁸ Joshua M. Hare,³ Peter Mundel,⁹ Azorides Morales,¹⁰ Julia Scialla,¹ Michael Fischer,^{11,12} Elsayed Z. Soliman,¹³ Jing Chen,¹⁴ Alan S. Go,¹⁵ Sylvia E. Rosas,¹⁶ Lisa Nessel,¹⁷ Raymond R. Townsend,¹⁶ Harold I. Feldman,^{16,17} Martin St. John Sutton,¹⁸ Akinlolu Ojo,¹⁹ Crystal Gadegbeku,²⁰ Giovana Seno Di Marco,²¹ Stefan Reuter,²¹ Dominik Kentrup,²¹ Klaus Tiemann,²² Marcus Brand,²¹ Joseph A. Hill,^{4,23} Orson W. Moe,^{4,6,24} Makoto Kuro-o,^{6,25} John W. Kusek,²⁶ Martin G. Keane,¹⁸ and Myles Wolf¹



Klotho and Phosphate Are Modulators of Pathologic Uremic Cardiac Remodeling


Ming Chang Hu,^{*†} Mingjun Shi,^{*} Han Jun Cho,^{*} Beverley Adams-Huet,^{*†‡} Jean Paek,^{*} Kathy Hill,^{*} John Shelton,[§] Ansel P. Amaral,^{||¶} Christian Faul,^{||¶} Masatomo Taniguchi,^{*‡} Myles Wolf,^{||} Markus Brand,^{**} Masaya Takahashi,^{††} Makoto Kuro-o,^{*§} Joseph A. Hill,^{†‡‡} and Orson W. Moe^{*†§§}

C




→ synergy of high-phosphate diet, Klotho deficiency and aging on cardiac remodelling

Physiologic processes




Pathologic processes - CKD




— Normal conditions
— Altered conditions

Cardiovascular pathology in CKD - crosstalk between kidney and cardiovascular system




- LVH
- cardiac fibrosis
- **impaired angioadaptation with reduced ischemia tolerance**
(role of VEGF and the sympathetic nervous system)
- accelerated arterio- and atherosclerosis
(calcification and (micro-) inflammation)

Decrease of myocardial capillarisation in CKD




control patient




CKD patient


mm/mm³



Myocyte-capillary mismatch in experimental CKD





sham





SNX

→ - 25% reduction of capillary supply
(can be prevented by blockade of the sympathetic nervous system and the ET system !)


Vascular maladaptation in CKD under ischemic conditions



-25%



Lack of adaptive VEGF-regulation in CKD under ischemic conditions (LVH and hind-limb)




sham







SNX

VEGF mRNA







VEGF-protein



The Soluble VEGF Receptor sFlt1 Contributes to Endothelial Dysfunction in CKD

Giovana S. Di Marco,^{*} Stefan Reuter,^{*} Uta Hillebrand,^{*†} Susanne Amler,[‡] Maximilian König,^{*} Etienne Larger,[§] Hans Oberleithner,[†] Eva Brand,^{*} Hermann Pavenstädt,^{*} and Marcus Brand^{*}










→ anti-angiogenic effect of CKD serum with ↑apoptosis of EC and ↓NO

Soluble Flt-1 links microvascular disease with heart failure in CKD

Giovana S. Di Marco¹ · Dominik Kentrup¹ · Stefan Reuter¹ · Anna B. Mayer¹ · Lina Golle¹ · Klaus Tiemann² · Manfred Fobker³ · Christiane Engelbertz⁴ · Günter Breithardt⁴ · Eva Brand¹ · Holger Reinecke⁴ · Hermann Pavenstädt¹ · Marcus Brand¹

Elevated sFLT-1 levels reduce capillary density in the heart



Cardiovascular pathology in CKD - crosstalk between kidney and cardiovascular system




- LVH
- cardiac fibrosis
- impaired angioadaptation with reduced ischemia tolerance
(role of VEGF and the sympathetic nervous system)
- **accelerated arterio- and atherosclerosis
(calcification and (micro-) inflammation)**

Accelerated arteriosclerosis in CKD - Uremic arteriopathy




fibrous or fibro-elastic intimal thickening




Epigastric artery of a 46y old patient at the time of renal transplantation


Wall thickening of coronary arteries in CKD



control



CKD



Arterial wall thickening in CKD is accompanied by ultrastructural changes



Normal morphology of aortic media (sham)




Media thickening with hyperplasia of VSMC, increased ECM and reduced elastic fibre content

→ reduced vascular elasticity, increased vascular wall stiffness, RR ↑, LVH ↑, calcification ↑

Atherosclerosis in CKD ?




more common ?

more severe ?



specific characteristics ?


Atherosclerosis in CKD




X-ray diffraction analysis of

→ pro-inflammatory phenotype of atherosclerotic plaques in CKD !

Cardiovascular pathology in CKD



Phenotypic alterations in uremia





ELSEVIER


Heart and Kidney: Fatal Twins?


Eberhard Ritz, MD

Department of Nephrology, Ruprecht-Karl University, Heidelberg, Germany



The pathologic mechanisms that underlie the progression of cardiovascular and renal damage are common to both, and this, coupled with evidence that renal damage can precipitate cardiovascular damage, reinforces the importance of targeting early renal disease with appropriate therapy in order to reduce the prevalence of cardiovascular disease. As has been succinctly summarized by de Zeeuw et al, we should “treat the kidney to protect the heart.”⁶¹





Thank you
very much !

Glomunculus